Last reviewed · How we verify
NCT06739980
The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency
Phase 2 trial testing INZ-701 in Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency. Withdrawn.
31 March 2027
Quick facts
| Lead sponsor | Inozyme Pharma |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 31 January 2025 |
| Primary completion | 31 March 2027 |
| Estimated completion | 31 March 2028 |
Drugs / interventions tested
- INZ-701 — full drug profile →
Conditions studied
- Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency — all drugs for Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency →
- Autosomal Recessive Hypophosphatemic Rickets — all drugs for Autosomal Recessive Hypophosphatemic Rickets →
- Generalized Arterial Calcification of Infancy 1 — all drugs for Generalized Arterial Calcification of Infancy 1 →
Sponsor
Inozyme Pharma — full company profile →
Who can join
1 and older, any sex, with Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency or Autosomal Recessive Hypophosphatemic Rickets. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of Study INZ701-108 (ENABLE) is to assess the safety and efficacy of INZ-701 in patients 1 year of age and older with ENPP1 Deficiency who have not previously received INZ-701 and are not eligible for existing Inozyme-sponsored clinical studies that are still open to enrollment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06739980
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of INZ-701
Trials testing the same drug.
- NCT07473973 — ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency · Phase 3 · recruiting
- NCT06283589 — The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Underg · Phase 1 · completed
- NCT05734196 — The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency · Phase 1 · recruiting
- NCT05030831 — Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE · Phase 1, PHASE2 · completed
- NCT04686175 — Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency · Phase 1, PHASE2 · completed
Other recruiting trials for Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Currently open trials in the same condition.
- NCT07473973 — ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency · Phase 3 · recruiting
- NCT05734196 — The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency · Phase 1 · recruiting
Other Inozyme Pharma trials
Trials by the same sponsor.
- NCT07473973 — ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency · Phase 3 · recruiting
- NCT06283589 — The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Underg · Phase 1 · completed
- NCT05734196 — The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency · Phase 1 · recruiting
- NCT05050669 — Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency · completed
- NCT05030831 — Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06739980 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Inozyme Pharma
- Last refreshed: 1 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06739980.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing